

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7708642

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JEREMY R. DUVALL	04/27/2021
KEITH W. BENTLEY	05/05/2021
RAGHIDA A. BUKHALID	06/04/2021
NANIYE CETINBAS	06/07/2021
MARC I. DAMELIN	05/14/2021
EUGENE W. KELLEHER	04/27/2021
TIMOTHY B. LOWINGER	05/24/2021
JOSHUA D. THOMAS	04/27/2021
DORIN TOADER	05/16/2021
LING XU	04/27/2021
LIPING YANG	05/25/2021
RECEIVING PARTY DATA	
Name:	MERSANA THERAPEUTICS, INC.
Street Address:	840 MEMORIAL DRIVE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	18068476
Application Number:	18068936
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6179372300
Email:	fvandermaelen@cooley.com
Correspondent Name:	COOLEY LLP, ATTN: PATENT GROUP
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	SUITE 700

Address Line 4: WASHINGTON, D.C. 20004	
ATTORNEY DOCKET NUMBER:	MRSN-033
NAME OF SUBMITTER:	CHRISTINE E. DUNNE
SIGNATURE:	/Christine E. Dunne/
DATE SIGNED:	12/22/2022
Total Attachments: 15 source=MRSN-033 - Assignment#page1.tif source=MRSN-033 - Assignment#page2.tif source=MRSN-033 - Assignment#page3.tif source=MRSN-033 - Assignment#page4.tif source=MRSN-033 - Assignment#page5.tif source=MRSN-033 - Assignment#page6.tif source=MRSN-033 - Assignment#page7.tif source=MRSN-033 - Assignment#page8.tif source=MRSN-033 - Assignment#page9.tif source=MRSN-033 - Assignment#page10.tif source=MRSN-033 - Assignment#page11.tif source=MRSN-033 - Assignment#page12.tif source=MRSN-033 - Assignment#page13.tif source=MRSN-033 - Assignment#page14.tif source=MRSN-033 - Assignment#page15.tif	

ASSIGNMENT

Jeremy R. DUVALL, residing at 27 Paon Boulevard, Wakefield, MA 01880; **Keith W. BENTLEY**, residing at 25 Charlton St., Apt 208, Everett, MA 02149; **Raghida A. BUKHALID**, residing at 150 Rivers Edge Drive, Apt. 390, Medford, MA 02155; **Naniye CETINBAS**, residing at 249 Third Street, Apt. 404, Cambridge, MA 02138; **Marc I. DAMELIN**, residing at 42 Lexington Avenue, Needham, MA 02494; **Eugene W. KELLEHER**, residing at 20 Sunnyside Avenue, Wellesley, MA 02482; **Timothy B. LOWINGER**, residing at 352 School Street, Carlisle, MA 01741; **Joshua D. THOMAS**, residing at 83 Bacon Street, Natick, MA 01760; **Dorin TOADER**, residing at 1699 Cambridge Street, Apt. 32, Cambridge, MA 02138; **Ling XU**, residing at 6 Still Street, Unit 1, Brookline, MA 02446; and **Liping YANG**, residing at 53 Wilbur Avenue, Arlington, 02476 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS**, and which is a:

- (1) ☐ provisional application
 - (a) ☐ to be filed herewith; or
 - (b) ☐ bearing Application No. , and filed on ;
- (2) ☒ non-provisional application
 - (a) ☐ to be filed herewith; or
 - (b) ☒ bearing Application No. 17/221,341, and filed on April 2, 2021; and/or
- (3) ☒ PCT application
 - (a) ☒ bearing Application No. PCT/US21/25556, and filed on April 2, 2021.

and/or
- (4) ☐ attached hereto.

WHEREAS, Mersana Therapeutics, Inc., having its principal place of business at 840 Memorial Drive, Cambridge, MA 02139, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present,

and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.


The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 4/27/2021


By: 
Jeremy R. Duvall

Witness Signature:  Date: 4/27/2021


Print Witness Name: EUGENE W. KELLEHER


Witness Signature:  Date: 4/27/21


Print Witness Name: Joshua D Thomas


Date: 5-5-21 By: 
Keith W. Bentley

Witness Signature:  Date: 5/5/2021
Print Witness Name: EUGENE KELLEHER

Witness Signature:  Date: 5/5/21
Print Witness Name: Nabeeh Kaur

Date: 6/4/2021 By: 
Raghida A. Bukhalid


Witness Signature:  Date: 6/4/21
Print Witness Name: PHONHIMON WONGTHIDA


Witness Signature:  Date: 6/4/21
Print Witness Name: Travis S. Marshall


Date: 6/7/2021 By: B. Naniye
Naniye Cetinbas

Witness Signature: Matthew A. Crowe Date: 6/7/21
Print Witness Name: Matthew S. Crowe


Witness Signature: Chelsey Faircloth Date: 6/7/21
Print Witness Name: Chelsey Faircloth


Date: 5/14/2021 By: 
Marcel Damelin


Witness Signature:  Date: 5/14/2021
Print Witness Name: MARSHA SLOTNICK

Witness Signature:  Date: 5/14/21
Print Witness Name: Rebecca J Shimshek

Date: 4/27/2021

By: 
Eugene W. Kelleher

Witness Signature:  Date: 4/27/21
Print Witness Name: Joshua Thomas


Witness Signature:  Date: 4/27/2021
Print Witness Name: Jeremy R. Duvall


Date: May 24, 2021 By: Timothy B. Lowinger
Timothy B. Lowinger

Witness Signature: Kyoko Lowinger Date: May 24, 2021
Print Witness Name: KYOKO LOWINGER


Witness Signature: Noah Lowinger Date: May 24, 2021
Print Witness Name: NOAH LOWINGER

Date: 4/27/21

By: 
Joshua D. Thomas


Witness Signature:  Date: 4/27/2021


Print Witness Name: EUGENE W. KELLEHER

Witness Signature:  Date: 4/27/2021


Print Witness Name: Jeremy B. Duvall

Date: 5-16-21

By: 
Dorin Toader

Witness Signature:  Date: 5.16.2021

Print Witness Name: SORIN MARCOVICI

Witness Signature:  Date: 5.16.2021


Print Witness Name: CECILIA MARCOVICI


Date: April 27, 2021 By: Ling Xu
Ling Xu

Witness Signature: ELC CL Date: 04/27/2021
Print Witness Name: ELAINE CHEN


Witness Signature: Tong Chen Date: 04/27/2021
Print Witness Name: TONG CHEN

Date: 5/25/21

By: 
Liping Yang

Witness Signature:  Date: 5/25/21

Print Witness Name: Ning Li

Witness Signature:  Date: 5/25/21

Print Witness Name: Wei Xie

For and on behalf of ASSIGNEE:

Date: May 24, 2021

By: Timothy B. Lowmuck
Name: Timothy B. Lowmuck
Title: CHIEF SCIENCE & TECHNOLOGY OFFICER
Company: Mersana Therapeutics, Inc.

Witness Signature: Kyoko Lowmuck Date: May 24, 2021
Print Witness Name: Kyoko Lowmuck

Witness Signature: Noah Lowmuck Date: May 24, 2021
Print Witness Name: Noah Lowmuck